Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies

Front Immunol. 2023 Dec 6:14:1270011. doi: 10.3389/fimmu.2023.1270011. eCollection 2023.

Abstract

Multi-antibody-positive myasthenia gravis (MG) presentations are relatively rare, often found in older patients, and generally predict a poor prognosis. We report a case of a female patient with generalized MG, testing positive for Titin antibodies (Titin-Ab), ryanodine receptor antibodies (RyR-Ab), and acetylcholine receptor antibodies (AChR-Ab), and resistant to acetylcholinesterase inhibitors. Following unsuccessful traditional therapies, she received Telitacicept, leading to significant improvements. This case underscores Telitacicept's potential efficacy for similar patients and offers insights into the clinical characteristics of multi-antibody MG.

Keywords: AChR-Ab; RyR-Ab; Telitacicept; Titin-Ab; case report; myasthenia gravis.

Publication types

  • Case Reports

MeSH terms

  • Acetylcholinesterase
  • Aged
  • Autoantibodies
  • Connectin
  • Female
  • Humans
  • Myasthenia Gravis* / diagnosis
  • Myasthenia Gravis* / drug therapy
  • Thymoma*
  • Thymus Neoplasms*

Substances

  • Connectin
  • telitacicept
  • Acetylcholinesterase
  • Autoantibodies

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.